Gastroenterologists Adherence to Tumor Necrosis Factor Antagonist Combination Therapy in Inflammatory Bowel Disease

Introduction: Tumor necrosis factor antagonists (anti-TNF) therapies are used for the management of moderate to severe inflammatory bowel disease (IBD). Anti-TNF combination therapy, with immunomodulators, has been shown to reduce immunogenicity, especially for infliximab, improve treatment success...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdullah, Israa, Alhendi, Ghadeer, Alhadab, Anwar, Alasfour, Hajer, Shehab, Mohammad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8511459/
https://www.ncbi.nlm.nih.gov/pubmed/34660635
http://dx.doi.org/10.3389/fmed.2021.725512

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8511459/
https://www.ncbi.nlm.nih.gov/pubmed/34660635
http://dx.doi.org/10.3389/fmed.2021.725512

Ejemplares similares